RU2013103995A - Диагностика колоректального рака - Google Patents
Диагностика колоректального рака Download PDFInfo
- Publication number
- RU2013103995A RU2013103995A RU2013103995/15A RU2013103995A RU2013103995A RU 2013103995 A RU2013103995 A RU 2013103995A RU 2013103995/15 A RU2013103995/15 A RU 2013103995/15A RU 2013103995 A RU2013103995 A RU 2013103995A RU 2013103995 A RU2013103995 A RU 2013103995A
- Authority
- RU
- Russia
- Prior art keywords
- level
- biomarkers
- colorectal cancer
- mmp
- m2pk
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
- C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57407—Specifically defined cancers
- G01N33/57419—Specifically defined cancers of colon
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
- G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
- G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
- G01N33/57488—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites involving compounds identifable in body fluids
-
- G01N33/57535—
-
- G01N33/5758—
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/118—Prognosis of disease development
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Organic Chemistry (AREA)
- Pathology (AREA)
- Analytical Chemistry (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Zoology (AREA)
- Physics & Mathematics (AREA)
- Biotechnology (AREA)
- Hospice & Palliative Care (AREA)
- Oncology (AREA)
- Microbiology (AREA)
- Biochemistry (AREA)
- General Health & Medical Sciences (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Biomedical Technology (AREA)
- Cell Biology (AREA)
- General Engineering & Computer Science (AREA)
- Biophysics (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Food Science & Technology (AREA)
- General Physics & Mathematics (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| AU2010903140 | 2010-07-14 | ||
| AU2010903140A AU2010903140A0 (en) | 2010-07-14 | Diagnostic for colorectal cancer | |
| PCT/AU2011/000895 WO2012006681A1 (en) | 2010-07-14 | 2011-07-14 | Diagnostic for colorectal cancer |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2013103995A true RU2013103995A (ru) | 2014-08-20 |
Family
ID=45468816
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2013103995/15A RU2013103995A (ru) | 2010-07-14 | 2011-07-14 | Диагностика колоректального рака |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US20130345322A1 (enExample) |
| EP (2) | EP2829881B1 (enExample) |
| JP (1) | JP6061344B2 (enExample) |
| CN (2) | CN103140760B (enExample) |
| AU (1) | AU2011279555B2 (enExample) |
| BR (1) | BR112013000745B1 (enExample) |
| DK (1) | DK2829881T3 (enExample) |
| ES (1) | ES2653646T3 (enExample) |
| IN (1) | IN2013CN01129A (enExample) |
| NO (1) | NO2829881T3 (enExample) |
| PT (1) | PT2829881T (enExample) |
| RU (1) | RU2013103995A (enExample) |
| WO (1) | WO2012006681A1 (enExample) |
Families Citing this family (34)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| ES2653646T3 (es) * | 2010-07-14 | 2018-02-08 | Vision Tech Bio Pty Ltd | Diagnóstico para cáncer colorrectal |
| US9141756B1 (en) | 2010-07-20 | 2015-09-22 | University Of Southern California | Multi-scale complex systems transdisciplinary analysis of response to therapy |
| US20140037642A1 (en) | 2011-02-02 | 2014-02-06 | Amgen Inc. | Methods and compositions relating to inhibition of igf-1r |
| HUE042708T2 (hu) * | 2012-08-09 | 2019-07-29 | Inst Nat Sante Rech Med | Szívelégtelenség diagnosztika |
| GB201218341D0 (en) * | 2012-10-12 | 2012-11-28 | Orign Sciences Ltd | Diagnostic method |
| CA2943827A1 (en) * | 2014-03-28 | 2015-10-01 | Applied Proteomics, Inc. | Protein biomarker profiles for detecting colorectal tumors |
| JP6685276B2 (ja) * | 2014-07-18 | 2020-04-22 | サノフイＳａｎｏｆｉ | 癌に罹患していることが疑われる患者のアフリベルセプトを用いた処置の結果を予測するための方法 |
| CN106191215B (zh) * | 2015-04-29 | 2020-03-24 | 中国科学院上海生命科学研究院 | 肌肉萎缩相关的蛋白质分子标记Dkk-3的筛选及其应用 |
| EP3294321B1 (en) * | 2015-05-12 | 2024-07-31 | Superlab Far East Limited | Methods of determining interferon having direct inhibitory effects on tumors and uses thereof |
| CN105219844B (zh) * | 2015-06-08 | 2018-12-14 | 华夏京都医疗投资管理有限公司 | 一种筛查十一种疾病的基因标志物组合、试剂盒以及疾病风险预测模型 |
| CN105021828B (zh) * | 2015-07-20 | 2017-07-28 | 上海交通大学医学院附属新华医院 | 通过检测三期结直肠肿瘤患者血清预测肿瘤患者预后 |
| CN105567846A (zh) * | 2016-02-14 | 2016-05-11 | 上海交通大学医学院附属仁济医院 | 检测粪便中细菌dna的试剂盒及其在大肠癌诊断中的应用 |
| JP6984862B2 (ja) * | 2017-03-15 | 2021-12-22 | 国立大学法人金沢大学 | 血中ケモカインをマーカーとして用いた大腸癌の検出 |
| CN107164535A (zh) * | 2017-07-07 | 2017-09-15 | 沈阳宁沪科技有限公司 | 一种无创高通量甲基化结肠癌诊断、研究和治疗方法 |
| CN110540588B (zh) * | 2018-05-28 | 2022-08-23 | 香港中文大学 | 一种基于肿瘤干细胞标志物EpCAM的抗原表位多肽及其应用 |
| CN108957014A (zh) * | 2018-09-27 | 2018-12-07 | 郑州大学第附属医院 | 结直肠癌血清标志物、表达评估方法、试剂盒及应用 |
| JP2022505676A (ja) * | 2018-10-23 | 2022-01-14 | ブラックソーン セラピューティクス インコーポレイテッド | 患者のスクリーニング、診断、及び層別化のためのシステム及び方法 |
| CN109504778B (zh) * | 2019-01-11 | 2021-11-09 | 复旦大学附属中山医院 | 一种基于表观修饰的5hmC多分子标志物及结直肠癌早期诊断模型 |
| CN113785199B (zh) * | 2019-03-01 | 2024-02-09 | 先进标志物探索公司 | 用于诊断结肠直肠癌和/或其癌前阶段的蛋白质特征 |
| JP7032764B2 (ja) * | 2019-04-03 | 2022-03-09 | 京都府公立大学法人 | 大腸がんの検出方法 |
| JP7300660B2 (ja) * | 2019-04-03 | 2023-06-30 | 京都府公立大学法人 | 大腸がんの検出方法 |
| GB201906199D0 (en) * | 2019-05-02 | 2019-06-19 | Belgian Volition Sprl | Method for the detection of cancer |
| US20220378877A1 (en) * | 2019-11-13 | 2022-12-01 | University Of Virginia Patent Foundation | Treatment of clostridium difficile infections |
| EP3835789A1 (en) | 2019-12-13 | 2021-06-16 | Deutsches Krebsforschungszentrum, Stiftung des öffentlichen Rechts | Biomarker panel for diagnosing colorectal cancer |
| WO2022130597A1 (ja) * | 2020-12-18 | 2022-06-23 | 国立大学法人東北大学 | 推定装置、推定方法、推定プログラム、生成装置、及び、推定システム |
| JP2024505333A (ja) * | 2020-12-21 | 2024-02-06 | フリーノム ホールディングス，インク． | 結腸細胞増殖障害の早期検出のためのマーカー |
| AU2022259871A1 (en) * | 2021-04-20 | 2023-11-23 | Vision Tech Bio Pty Ltd | Biomarkers for colorectal cancer |
| CN118251595A (zh) * | 2021-08-11 | 2024-06-25 | 视觉技术生物有限公司 | 检测腺瘤的方法 |
| WO2023128429A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 진행 선종의 선별 검사 방법 및 그 응용 |
| WO2023128419A1 (ko) * | 2021-12-31 | 2023-07-06 | 주식회사 이노제닉스 | 대장암 및 대장 용종 또는 진행 선종의 선별 방법 및 그 응용 |
| CN114594259B (zh) * | 2022-04-22 | 2022-09-13 | 北京易科拜德科技有限公司 | 一种新型的用于结直肠癌预后预测和诊断的模型及其应用 |
| PL441319A1 (pl) * | 2022-05-31 | 2023-12-04 | Uniwersytet Medyczny Im. Piastów Śląskich We Wrocławiu | Zestaw biomarkerów białkowych i sposób diagnostyki raka jelita grubego in vitro |
| CN116219007A (zh) * | 2022-09-15 | 2023-06-06 | 绍兴积准生物科技有限公司 | 检测结直肠癌的生物标志物组及其应用 |
| CN119688988A (zh) * | 2024-11-25 | 2025-03-25 | 中国医学科学院肿瘤医院 | Timp1和foxp3作为诊断结直肠癌的生物标志物组合及其应用 |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5925517A (en) | 1993-11-12 | 1999-07-20 | The Public Health Research Institute Of The City Of New York, Inc. | Detectably labeled dual conformation oligonucleotide probes, assays and kits |
| JP2004198419A (ja) * | 2002-12-13 | 2004-07-15 | Bayer Healthcare Llc | Ｔｉｍｐ１を用いた検出方法 |
| US20050014165A1 (en) * | 2003-07-18 | 2005-01-20 | California Pacific Medical Center | Biomarker panel for colorectal cancer |
| DE602004030586D1 (de) * | 2003-09-15 | 2011-01-27 | Oklahoma Med Res Found | Verfahren zur verwendung von cytokintests zur diagnose, behandlung und beurteilung von ankyloider spondylitis |
| BRPI0401830A (pt) | 2004-05-25 | 2006-01-17 | Bentonit Uniao Nordeste Sa | Processo de produção de pós granulados secos |
| ATE537450T1 (de) * | 2006-06-30 | 2011-12-15 | Schering Corp | Igfbp2-biomarker |
| WO2008073660A1 (en) | 2006-11-09 | 2008-06-19 | University Of Washington | Molecules and methods for treatment and detection of cancer |
| EP2094719A4 (en) * | 2006-12-19 | 2010-01-06 | Genego Inc | NEW PROCEDURES FOR THE FUNCTIONAL ANALYSIS OF EXPERIMENTAL HIGH-PERFORMANCE DATA AND IDENTIFIED GENDER GROUPS THEREOF |
| US20080221056A1 (en) | 2007-02-12 | 2008-09-11 | Johns Hopkins University | Early Detection and Prognosis of Colon Cancers |
| DK2472264T3 (en) * | 2007-02-27 | 2016-02-29 | Sentoclone Internat Ab | Multiplekspåvisning of tumor cells using a panel of agents which bind to extracellular markers |
| WO2008116178A2 (en) * | 2007-03-21 | 2008-09-25 | Vanderbilt University | Systems and methods for diagnosis and prognosis of colorectal cancer |
| CA2684024A1 (en) * | 2007-05-10 | 2008-11-20 | F. Hoffmann-La Roche Ag | Use of timp-1 as a marker for colorectal cancer |
| WO2008144345A2 (en) * | 2007-05-17 | 2008-11-27 | Bristol-Myers Squibb Company | Biomarkers and methods for determining sensitivity to insulin growth factor-1 receptor modulators |
| EP2171470A2 (en) * | 2007-06-04 | 2010-04-07 | Diagnoplex | Biomarker combinations for colorectal cancer |
| US20090017463A1 (en) * | 2007-07-10 | 2009-01-15 | Vanderbilt University | Methods for predicting prostate cancer recurrence |
| US20110059464A1 (en) * | 2008-04-08 | 2011-03-10 | Muraca Patrick J | Biomarker Panel For Prediction Of Recurrent Colorectal Cancer |
| US20100111969A1 (en) * | 2008-10-31 | 2010-05-06 | Apogenix Gmbh | Il-4 receptor and il-13 as prognostic markers for colon and pancreas tumors |
| US20100173024A1 (en) * | 2008-12-01 | 2010-07-08 | LifeSpan Extension, LLC | Methods and compositions for altering health, wellbeing, and lifespan |
| US20110236903A1 (en) * | 2008-12-04 | 2011-09-29 | Mcclelland Michael | Materials and methods for determining diagnosis and prognosis of prostate cancer |
| US9354233B2 (en) * | 2009-02-20 | 2016-05-31 | The Regents Of The University Of California | A+ biomarker assays |
| US20110177525A1 (en) * | 2010-01-19 | 2011-07-21 | Predictive Biosciences, Inc. | Antibodies and methods of diagnosing diseases |
| ES2653646T3 (es) * | 2010-07-14 | 2018-02-08 | Vision Tech Bio Pty Ltd | Diagnóstico para cáncer colorrectal |
-
2011
- 2011-07-14 ES ES14178981.8T patent/ES2653646T3/es active Active
- 2011-07-14 CN CN201180034158.5A patent/CN103140760B/zh active Active
- 2011-07-14 EP EP14178981.8A patent/EP2829881B1/en active Active
- 2011-07-14 NO NO14178981A patent/NO2829881T3/no unknown
- 2011-07-14 AU AU2011279555A patent/AU2011279555B2/en active Active
- 2011-07-14 EP EP11806149.8A patent/EP2593795A4/en not_active Withdrawn
- 2011-07-14 PT PT141789818T patent/PT2829881T/pt unknown
- 2011-07-14 BR BR112013000745-1A patent/BR112013000745B1/pt not_active IP Right Cessation
- 2011-07-14 DK DK14178981.8T patent/DK2829881T3/en active
- 2011-07-14 JP JP2013518909A patent/JP6061344B2/ja active Active
- 2011-07-14 WO PCT/AU2011/000895 patent/WO2012006681A1/en not_active Ceased
- 2011-07-14 IN IN1129CHN2013 patent/IN2013CN01129A/en unknown
- 2011-07-14 CN CN201511009181.5A patent/CN105755112B/zh active Active
- 2011-07-14 US US13/809,785 patent/US20130345322A1/en not_active Abandoned
- 2011-07-14 RU RU2013103995/15A patent/RU2013103995A/ru not_active Application Discontinuation
-
2017
- 2017-03-28 US US15/471,147 patent/US10877039B2/en active Active
Also Published As
| Publication number | Publication date |
|---|---|
| JP6061344B2 (ja) | 2017-01-18 |
| ES2653646T3 (es) | 2018-02-08 |
| IN2013CN01129A (enExample) | 2015-07-31 |
| EP2829881B1 (en) | 2017-08-23 |
| US20130345322A1 (en) | 2013-12-26 |
| EP2593795A1 (en) | 2013-05-22 |
| EP2829881A3 (en) | 2015-05-13 |
| US20170205414A1 (en) | 2017-07-20 |
| NO2829881T3 (enExample) | 2018-01-20 |
| BR112013000745A2 (pt) | 2016-05-24 |
| CN103140760A (zh) | 2013-06-05 |
| AU2011279555A1 (en) | 2013-01-31 |
| CN105755112B (zh) | 2019-06-07 |
| EP2829881A2 (en) | 2015-01-28 |
| EP2593795A4 (en) | 2014-01-22 |
| PT2829881T (pt) | 2017-11-29 |
| US10877039B2 (en) | 2020-12-29 |
| CN103140760B (zh) | 2016-01-27 |
| CN105755112A (zh) | 2016-07-13 |
| DK2829881T3 (en) | 2017-12-04 |
| AU2011279555B2 (en) | 2016-10-20 |
| JP2013533977A (ja) | 2013-08-29 |
| WO2012006681A1 (en) | 2012-01-19 |
| BR112013000745B1 (pt) | 2021-02-02 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2013103995A (ru) | Диагностика колоректального рака | |
| JP2013533977A5 (enExample) | ||
| Yazdan-Ashoori et al. | Elevated plasma matrix metalloproteinases and their tissue inhibitors in patients with severe sepsis | |
| Dragutinović et al. | Matrix metalloproteinase-2 (MMP-2) and-9 (MMP-9) in preoperative serum as independent prognostic markers in patients with colorectal cancer | |
| CN115005778A (zh) | 用于手术后感染的早期检测的系统和方法 | |
| TR201907389T4 (tr) | Meme kanserinden kaynaklanan metastazlı kemik kanserinin prognozu ve tedavisine yönelik yöntem. | |
| US20140271453A1 (en) | Methods for the early detection of lung cancer | |
| CN116559453A (zh) | 一种用于肺癌检测的生物标志物 | |
| Dong et al. | High levels of TRIM14 are associated with poor prognosis in hepatocellular carcinoma | |
| Molad et al. | Soluble triggering receptor expressed on myeloid cells‐1 is a biomarker of anti‐CCP‐positive, early rheumatoid arthritis | |
| Singh et al. | Idiopathic pulmonary fibrosis: where do we stand and how far to go | |
| Jeong et al. | Significance of the DNA-histone complex level as a predictor of major adverse cardiovascular events in hemodialysis patients: the effect of uremic toxin on DNA-histone complex formation | |
| Confield et al. | Vibrational spectroscopic analysis of blood for diagnosis of infections and sepsis: a review of requirements for a rapid diagnostic test | |
| CN116519954A (zh) | 一种结直肠癌检测模型构建方法、系统及生物标志物 | |
| Paulo et al. | Mass spectrometry-based (GeLC-MS/MS) comparative proteomic analysis of endoscopically (ePFT) collected pancreatic and gastroduodenal fluids | |
| David et al. | Low serum uromodulin levels and their association with lupus flares | |
| Saichua et al. | Levels of 8-OxodG predict hepatobiliary pathology in Opisthorchis viverrini endemic settings in Thailand | |
| Deng et al. | Lipocalin2 as a useful biomarker for risk stratification in patients with acute cholangitis: a single-center prospective and observational study | |
| Toson et al. | Fibrogenic/angiogenic linker for non-invasive assessment of hepatic fibrosis staging in chronic hepatitis C among Egyptian patients | |
| ES2932268T3 (es) | Biomarcadores de aterosclerosis subclínica | |
| Ziloochian et al. | Investigating the relationship between plasma D-Dimer levels and clinical outcomes in COVID-19 patients admitted to Shahid Beheshti hospital in Kashan | |
| Shimizu et al. | The clinical significance of serum procalcitonin levels following direct hemoperfusion with polymyxin B-immobilized fiber column in septic patients with colorectal perforation | |
| RU2014154144A (ru) | Аутоиммунные антитела | |
| WO2020140425A1 (zh) | 一组血清差异蛋白组合在制备用于检测孤独症的试剂中的应用 | |
| Salih et al. | Salivary matrix metalloproteinase-8 indicate the severity of diabetic foot ulcer. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| HC9A | Changing information about inventors | ||
| FA92 | Acknowledgement of application withdrawn (lack of supplementary materials submitted) |
Effective date: 20170307 |